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Summary. The records of 194 patients with thyroid carcinoma treated with 1311,
representing all cases thus treated in. Denmark from 1948 to 1972, were reviewed.
Two cases of myeloid leukaemia were found compared with 0*097 expected cases
of non-lymphocytic leukaemia (0.05 > P > 0.01). In 5 series of 131I treated thyroid
carcinomata,,10 cases of myeloid leukaemia occurred in a total of 487 patients, cor-
responding to a frequency of leukaemia of about 2%. These findings appear to
show that 1311 treatment of thyroid carcinoma is associated with a certain risk of
development of leukaemia. This risk must be considered when treatment of
localized thyroid carcinoma is planned.
DIRECT proof that ionizing radiation
induces leukaemia in man does not
exist, but there is a large body of sug-
gestive evidence (Anderson et al., 1972;
Cronkite, Moloney and Bond, 1960; Re-
port of the United Nations Scientific
Committee, 1972) indicating that leuk-
aemia, predominantly of the myeloid
variety, may be induced in individuals
exposed to ionizing radiation accidentally
or for diagnostic or therapeutic reasons.
In very large series ofpatients (Pochin,
1961; Saenger, Thoma and Tompkins,
1968) treated with relatively low doses
of 1311 for hyperthyroidism, no evidence
has been found of an increased leukaemia
risk which could be attributed to the
treatment.
High doses of 131I have been employed
in the treatment of thyroid carcinoma.
Since 1953 a total of 11 cases ofleukaemia
arising in patients treated for thyroid
carcinoma with 131I have been reported
in 7 publications (Blom, Querido and
Leeksma, 1955; Delarue, Tubiana and
Dutriex, 1953; Jeliffe and Jones, 1960;
Lewallen and Godwin, 1963; Ozarda,
Ergin and Bender, 1961; Pochin, 1961;
Seidlin et al., 1955). The cases are
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summarized in Table I. Nine of the 11
patients quoted in the literature were
women; all cases had developed within
5 years of the start of treatment and all
cases were myeloid leukaemias. Unfor-
tunately the total number of patients
treated was mentioned in only 2 of these
reports (Pochin, 1961; Seidlin et al.,
1955) so that a combined estimate cannot
be made of the leukaemia risk in the 7
treatment series. In Pochin's series of
215 patients (Pochin, 1969) 4 cases of
leukaemia occurred compared with 0.08
cases expected during the observation
period. This difference is highly signi-
ficant.
MATERIAL AND METHODS
All cases of thyroid carcinoma treated
with 131I in Denmark from 1948 until the
end of 1972 were reviewed. All patients
who had been given more than 50 mCi of
1311 were included in the material, consisting
of 194 who had received from 50 to 1313 mCi
of 131I during the course of their disease.
All patients have been followed until death
or until the end ofthe study.
Table II shows the number of patients
starting 1311 treatment for each year of the
study, the sex distribution, the number of
Radium Centre, the Finsen Institute, Copenhagen.
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TABLE I.-Cases ofLeukaemia Associated with 131I Treatment ofThyroid Carcinoma
Source
Delarue et al., 1953
Blom et al., 1955
Seidlin et al., 1955
Jeliffe et al., 1960
Ozarda et al., 1961
Pochin, 1961, 1969
Lewallen et at., 1963
Present series, 1973
Sex and age
at first dose
F 23
F 51
M 58
F 61
F 47
F 70
F 53
F 54
M 66
F 54
F 55
F 75
F 75
Mean value
Total dose
of 1311
(mCi)
324
261
1455
1600
400
346
1715
1130
1430
1280
805
483
600
Interval to
leukaemia
(years)
2 9/12
10/12
4
5
2
3 4/12
3 11/12
3 5/12
2 8/12
3
3 8/12
7
11/12
Type of
leukaemia
AML
AML
AML AML
AML
CML
AML
AML
AML
AML
AML
AML
CML
Total number of
patients treated
Unknown
Unknown
16
Unknown
22 (1)
215
40 (2)
194
910 mCi 3 years
Abbreviations: AML = acute myeloid leukaemia. CML = chronic myeloid leukaemia.
(1) Bender, personal communication. (2) Cronkite, personal communication.
TABLE II.-Number ofPatients Treatedper
Year and Patient Years at Risk
Number of
patients
treated
Men Women
1
3
2
1 2
2
2
2
3
2 1
2
5 2
2 4
1 4
3
4 4
3 11
4 16
3 18
5 10
2 16
5 10
10 13
2 9
1 3
50 144
Year of
diag-
nosis
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
Patient
years
at risk
1
4
6
7
9
9
8
9
10
12
13
19
21
25
26
34
47
62
74
76
87
92
100
98
83
930
Leukaemia
incidence,
source
reference
1943-57
Clemmesen
1964
1958-62
Clemmesen,
1969
1963-67
Clemmesen
(personal
communica-
tion)
patient-years at risk and the source reference
for the incidence of leukaemia used for the
calculations. For the last 10 years a mean
of 15 patients per year have been treated
with 131J for thyroid carcinoma, correspond-
ing to about 4 of all cases of thyroid cancer
per year in Denmark (Clemmesen, 1964,
1969).
Fig. 1 shows the age distribution of this
series. It is seen that 33% of the patients
were more than 70 years old when first
diagnosed and 59% of the patients were
more than 60 years old.
Survival was calculated by the actuarial
method without correction for mortality
from other causes including age: 50%
survival was 4*7 years and 25% survival was
9.7 years.
Two cases of leukaemia developing after
1311 treatment were found (see below).
The expected number of leukaemia cases
occurring in the 194 patients from the start
of 131I treatment until death or the end
of the study was calculated on the basis
of published Danish leukaemia incidence
rates for the years 1943-62 (Clemmesen,
1964, 1969). For the years 1963-72 the
latest available incidence rates for 1963-67
(Clemmesen) were used for the calculations
(Table II).
To obtain an additional estimate of the
risk of developing leukaemia after treatment
with 1311, a brief questionnaire was sent to
the 5 institutions which had reported cases
of leukaemia arising after 1311 treatment
without stating the total number of patients
treated. It was asked how many patients
had been treated with 131J in all, and whether
further cases ofleukaemia had been observed.
A reply was obtained from only 2 of theseH. BRINCKER, H. S. HANSEN AND A. P. ANDERSEN
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institutions and the information received is
added in Table I. No further cases of
leukaemia had been observed by these two
institutions.
Case no. 1.-Female, born in 1889.
Previously in good health.
In October 1964 a follicular carcinoma
w%Aas found, involving the left lobe of the
thyroid gland. The tumour had metas-
tasized to the left cervical lymph nodes as
well as to the right pleura, with invasion
of the 4th rib.
Operative treatment was not attempted
and the patient was treated with 1311, a total
dose of 483.4 mCi being given during the
next 10 months. In June 1965 a moderate
myxoedema was found, and the patient
as thereafter treated with thyroid hormone.
Following the last treatment with 1311 in
August 1965 pancytopenia developed with
the following minimum values: Hb 6 g/
100 mnl, leucocytes 1900/mm3, and platelets
60,000/mm3. The differential count was
normal, with the exception of a relative
lymphocytosis.
By March 1966 the bone marrow had
partly recovered but the blood counts
remained subnormal for the rest of the
patient's life. The blood count was: plate-
lets about 150,000/mm3, leucocytes about
3500/mm3, and Hb about 9 g/100 ml. All
signs of activity of the thyroid cancer had
subsided and the patient remained in a
satisfactory condition for the followxing 5
years, with the exception of recurring
symptoms of anaemia. For this reason 29
units of blood were given in all betw een
August 1965 and April 1971. From Novem-
ber 1965 and onwards she was treated with
prednisolone.
In November 1971 the patient began to
feel very tired, with dyspnoea and anorexia,
and 3 weeks later she also became febrile
with signs of bronchopneumonia. Blood
examination now showed Hb 6-7 g/100 ml,
leucocytes 30,000/mm3, and platelets 15,000/ mm3. The differential count showed 63%
atypical immature monocytoid cells, 211% granulocytes, 4%o myelocytes and 11%
erythroblasts. A bone marrow study showed
the picture of an acute myelomonocytoid leukaemia.
The patient's condition deteriorated
rapidly in spite of antibiotic treatment and
blood transfusions, and she died in December
1971, one week after the diagnosis of acute leukaemia. The latter diagnosis was con-
firmed at autopsy, but no evidence was
found of the thyroid carcinoma or the
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metastases, which thus appeared to have been
cured completely by the treatment with 1311.
Case no. 2.-Female, born in 1892.
At 27 years of age she had been treated
for a thyroid ailment, probably a toxic
goitre. The patient possibly had x-ray
treatment of the thyroid gland, but records
of the treatment(s) given in 1919 are not
available. Otherwise she had always en-
joyed good health.
In July 1967 a large bilateral nodular
goitre w%Nas found which had grown slowly
foi 5 vears. For the preceding 2 months
the patient had been hoarse and subse-
quenitly a paralysis of the left recurrent
nerv-e wNas demonstrated.
IIn August 1967 a sub-total thyroidectomy
wa.s performed. A follicular carcinoma was
found in the left lobe and a colloid goitre in
the right lobe of the thyroid gland. The
operationi was considered to be non-radical
because the tumour was infiltrating the
soft-part structures of the left side of the
neclk. However, scanning studies with 1311
did not demonstrate pathological concentra-
tioIns of the isotope in this region.
From September 1967 to February 1969
600 InCi of 1311 was administered in 6 doses
and the patient was further treated with
thvroid hormone. No clinical or scinti-
graphic evidence of recurrence of the thyroid
carcinoma wNas found from the time of the
operation and up to the death of the patient.
In July 1968 blood counts, which had
prev-iously been entirely normal, showed
HI) 9-9 g/100 ml, leucocytes 42,000/mm3, and
platelets 1,800,000/mm3. The differential
couInt showed 10% myelocytes, 18% bands,
540/ neutrophils, 90o eosinophils, 1% mono-
cytes and 8% lymphocytes. A bone marrow
study showed a typical picture of chronic
mveloid leukaemia whereas an earlier bone
mairow study before 131J treatment had
been normal. There was no hepatic or
spleinic enlargement.
The patient was placed on Myleran treat-
meint which controlled the leukaemia effect-
ively. In June 1969, however, the patient,
who by then had become aged and frail,
succumbed to an attack of gastroenteritis.
She died at home and no autopsy was
performed.
RE.SULTS
The expected number of leukaemia
cases in this series is 0-205, if all types
of leukaemias are considered, while the
expected number of cases of myeloid
leukaemia is 0 097. If the 2 cases of
leukaemia found are compared with 0.205
cases expected the difference is not sig-
nificant (P > 0.05). However, if the
cases found are compared with an ex-
pected number for myeloid leukaemia
of 0.097, the result reaches significance
at the 50% level (0.05 > P > 0.01).
When we include our results with
those reported in the 4 series in which
information was available relating to the
number of patients treated, 10 cases of
leukaemia were observed in a total of
487 patients treated with 131. This
corresponds to a frequency of leukaemia
of about 20%.
DISCUSSION
The 2 cases of leukaemia found in
the present series conform to the general
pattern observed, being of the myeloid
variety. One of the patients, however,
was a case of chronic myeloid leukaemia
which has been described onlv once
before as associated with 1311 treatment
(Ozarda et al., 1961).
Although thyroid carcinoma is about
3 times inore frequent in women than in
men (Gowing, 1970), it is difficult to
explain why only 2 of the 14 leukaemia
cases were found in men. Data on
radiation leukaemogenesis appears to show
that in populations exposed to ionizing
radiation more men than women develop
leukaemia(Gibson etal., 1972;Reportofthe
UnitedNationsScientificCommittee, 1972).
As pointed out by Pochin (Pochin,
1969), the reported series of 1311 treated
thyroid carcinoma in which cases of
leukaemia occur may be " self-selected "
by the fact of a randomly high occurrence
of such cases. This criticism does not
apply to the present series which was
unselected, consisting of all the cases
treated inside a well-defined geographical
area (Denmark), where very reliable
cancer statistics are available.
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cluded from the calculations, the difference
between the number of cases of leukaemia
found in our series and the number of
cases expected is not statistically signi-
ficant. The combined evidence of the
present series plus all the reported series
is, however, very suggestive of radiation
leukaemogenesis, even if self-selection
plays a part. Especially noteworthy is
the total absence of reports of cases of
lymphatic leukaemia following 1311 treat-
ment, since patients with thyroid carci-
noma generally belong to age groups
which have a higher frequency of lym-
phatic than of myeloid leukaemia (Clem-
mesen, 1964, 1969).
The question may be posed whether
the leukaemia risk associated with 1311
treatment is of such a magnitude that
1311 cannot be considered to be the
treatment of choice in patients with
metastasizing iodine-uptaking thyroid car-
cinoma. If the risk of developing leuk-
aemia is about 2% within 3 years of 1311
treatment, as indicated by the combined
evidence, this risk is clearly not negligible.
It has been argued (Ozarda et al., 1961)
that " we do not have to worry about
the probabilitv of induced leukaemia
since the life expectancy of these patients
is not long enough for it to develop ".
This statement is challenged by the fact
that the median survival was 4 7 years
in the present series in spite of the fact
that 3300 of the patients were more than
70 years old (Fig. 1). 37 of those living
more than 4 years after the diagnosis of
thyroid carcinoma had received a total
dose of 1311 of less than 200 mCi. In
most cases of thyroid carcinoma this
dose must be considered to be too small
to control metastatic disease, and the
long survival of these patients must be
ascribed to additional treatment such as
surgery and/or external radiotherapy.
The treatment with 1311 does not appear
to have been justified in the majority of
these patients, and they were thus
exposed unnecessarilv to a treatment
associated with an increased incidence of
leukaemia.
There is no doubt that 1311 remains
the treatment of choice in metastasizing,
iodine-concentrating thyroid carcinoma.
However, 1311 should not be the primary
treatment of localized iodine-concentrat-
ing thyroid carcinoma which can be con-
trolled by other treatments not associated
with an increased incidence ofleukaemia.
Dr Johannes Clemmesen, the Danish
Cancer Registry, kindly placed the un-
published leukaemia incidence data for
the years 1963-67 at our disposal. Thanks
are due to Dr Merrill A. Bender, Roswell
Park Memorial Institute, and to Dr
Eugene P. Cronkite, Brookhaven National
Laboratory, for the very helpful informa-
tion given concerning the patients treated
at these two institutions.
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